Bavarian Nordic has sealed a deal with Shanghai-based Nuance Pharma to develop and market its respiratory syncytial virus (RSV) vaccine candidate across China and numerous Southeast Asian territories, if it gains approval.
The deal sees Bavarian Nordic receive an upfront payment of $12.5m and makes it eligible for future milestone payments of...








